Researchers have proposed 12 candidate indicators that act as a biological speedometer to measure how fast you are aging at a single point in time.
On September 17, 2026, a multi-institutional team published new research in Frontiers in Science proposing 12 candidate indicators that estimate how fast someone is aging at a single point in time. This concept introduces a crucial shift for active adults who prioritize physical capability and travel independence. Traditional longevity metrics usually focus on accumulated cellular wear. The new research proposes a single snapshot measurement intended to show your current rate of biological decline.
The research team was led by Steven N. Austad of the University of Alabama at Birmingham, Matt Kaeberlein of Optispan and the Dog Aging Institute, and Richard A. Miller of the University of Michigan. They published their findings to address a major bottleneck in longevity science. Waiting decades to see if an intervention extends human lifespan is highly impractical. These new candidate markers are designed to circumvent that waiting period by providing real-time physiological feedback.
The study authors compare conventional biological age measures to an automobile odometer. An odometer estimates the total accumulated wear over the lifetime of a vehicle. The newly proposed aging rate indicators, or ARIs, function much more like a speedometer. They are intended to estimate the current rate of change happening within the body right now.
The 12 candidate ARI categories cover a wide spectrum of physiological functions. They span molecular signaling, immune cell profiles, and metabolism. They also involve specific tissues including liver, skeletal muscle, brain, and adipose tissue. Specific candidates include cap-independent translation, MEK1/ERK signaling, MEK3/p38 signaling, and mTORC1 activity.
Other proposed indicators involve the ratio of pro-inflammatory to anti-inflammatory macrophages in adipose tissue. The candidate list also includes FNDC5 and doublecortin. It further names NF-κB p65 and brain derived neurotrophic factor, which is known as BDNF. The paper specifically identifies irisin and GPLD1 as candidate indicators that can be measured directly in plasma.
This plasma measurement is a critical step toward eventual non-invasive testing. These proposed indicators emerged primarily from comparisons involving multiple slow-aging mouse models. The researchers drew heavily on studies from the National Institute on Aging-supported Interventions Testing Program. This program examined interventions associated with longer mouse lifespan.
The tested models included genetic alterations, calorie restriction, and isoleucine restriction. The team also looked at pharmacological interventions like rapamycin, acarbose, 17α-estradiol and canagliflozin. They reviewed 14 lifespan-extending agents or combinations in the mouse program. Eight of these interventions increased lifespan by at least 12% in one or both sexes.
Identifying common biological responses across these distinct models forms the foundation of the ARI framework. According to the study authors as quoted by Technology Networks, rapamycin produced the largest reported single-agent effect in their review. It increased median lifespan by 23% in male mice and 26% in female mice. Finding indicators that align with such profound longevity results is highly valuable for scientists.
The authors estimate that successful ARI-guided studies could eventually make some mouse experiments approximately four times faster. These accelerated preclinical studies could also be conducted at roughly one-twentieth of the expense of full lifespan trials. The article clearly distinguishes these 12 candidate ARIs from DunedinPACE, a separate measure described as promising for assessing aging rates in clinical settings. The current paper does not identify DunedinPACE as one of its 12 proposed categories.
The scientists driving this research view the ARI framework as a critical tool for future studies. Matt Kaeberlein said that the central translation challenge in aging biology is determining whether an intervention actually changes the rate of aging. He added that validated ARIs could provide answers on a practical timescale. This prevents researchers from waiting years or decades for lifespan outcomes to become evident.
Richard A. Miller said ARIs might offer a faster and less expensive way to select drugs deserving further testing in mice. He suggested that ARIs could eventually show whether a drug produces molecular changes in healthy people resembling slow-aging mice. He emphasized that this remains a proposed use rather than an established human test. The primary current value lies in screening candidate interventions and identifying shared biological responses.
Steven N. Austad said ARIs could eventually support preventative-therapy development and human clinical trials completed in shorter timeframes. This potential efficiency reflects a broader shift in geroscience. The field is moving from merely describing the biology of aging toward testing practical interventions. Validated indicators would make evaluating these interventions significantly more precise.
For active adults who prioritize physical independence, the distinction between accumulated aging and current aging rate is vital. When you are planning a high-altitude hike, your real-time resilience matters immensely. Your body's ability to adjust to altitude relies on its current biological momentum. A slower rate of aging translates directly to faster recovery after strenuous sports like skiing.
Travel demands can easily expose a fast-running biological speedometer. After a grueling thirty hour transit to Tokyo, I realized my old strategy of just powering through was no longer working. I felt foggy for three days. I started digging into circadian biology and realized that timing my light exposure and fasting during the flight could completely shift my recovery.
Now, I never board a long haul flight without a precise schedule for when to eat and when to put on an eye mask. It is the difference between losing a week of your trip and hitting the ground running. Managing environmental stress properly might be one way we eventually influence our own aging rate indicators. A resilient system handles jet lag and physical exertion with far less lingering cellular damage.
The research does present significant caveats regarding how we interpret physical activity and biomarker changes. The paper specifically warns that exercise or mental activity could alter BDNF or FNDC5 without necessarily producing a broader slow-aging state. This is a critical nuance for anyone measuring their health after demanding physical activities. A favorable change in an exercise-responsive marker should not be automatically interpreted as proof of a slowed aging rate.
The indicators may also respond differently across tissues, sexes, ages, and specific longevity interventions. For example, the paper identifies an exception involving UCP1 in adipose tissue. UCP1 did not increase in white adipose tissue depots after rapamycin administration. This occurred even though the marker appeared consistently in other slow-aging animal models.
The 12 candidates are derived primarily from mouse research and remain entirely unvalidated in humans. No evidence in the cited sources shows that any candidate reliably measures an individual's aging rate in clinical practice today. The indicators are not a consumer checklist for immediate use. Incorporating four fitness measures that have real clinical backing is still the preferred strategy for active adults.
Understanding how different tissues age is a growing theme in longevity science. We already know that focusing on organ-specific aging research provides a better picture than a single biological age score. The newly proposed ARIs align with this targeted approach. They look at specific molecular pathways rather than providing a single arbitrary number.
Until human validation becomes available, practical health decisions should remain grounded in clinically established methods. Evidence continues to show that a structured lifestyle beats supplements when trying to manage your physical capability over time. The true promise of this framework is not an immediate consumer test. It is the hope that better validated measures will eventually make future interventions highly testable.
Until these aging rate indicators are validated for human clinical use, active adults should maintain their physical capability by prioritizing established, holistic health measures rather than reacting to single biomarker fluctuations.
Stay connected for research and practical guidance on longevity, strength, recovery, energy and active living. New ideas to help you stay capable, curious and ready for more.
Explore practical guidance on strength, recovery, energy, travel and longevity for a life that stays active.
explore the Blog
